Sign in
SNGX Stock Price, Chart, Stats & News
Soligenix, Inc.
Save
4.12M
Market cap
–
Current P/E
12.32x
Forward P/E
SNGX chart
1M
3M
1Y
5Y
Loading chart...
Fundamentals
Gross margin | – |
Operating margin | – |
Pretax margin | – |
Net margin | – |
Effective tax rate | 3.45% |
ROA | -101.44% |
ROE | -267.10% |
D/E | 0.05x |
Interest coverage ratio | – |
SNGX valuation
P/E | – |
P/S | – |
P/B | 0.64x |
P/CF | -0.50x |
P/FCF | -1.17x |
P/OCF | -0.50x |
PEG | -0.08x |
EV multiple | -1.75x |
About
Soligenix, Inc., a biopharmaceutical firm in its advanced development stages, concentrates on bringing innovative products to market within the United States, specifically targeting rare illnesses. The company's operations are divided into two main divisions: Specialized BioTherapeutics and Public Health Solutions. Within the Specialized BioTherapeutics division, Soligenix is advancing SGX301 (marketed as HyBryte), a novel photodynamic treatment that has successfully completed its Phase III clinical trials for managing cutaneous T-cell lymphoma.
Similar securities
Based on sector and market capitalization
Report issue